# Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

> **NCT02289456** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 40 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** nab-Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02289456
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-28
- **Primary completion:** 2017-02-22
- **Final completion:** 2017-02-22
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289456, "Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02289456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*